GSDME and congenital rubella syndrome: For future studies, researchers should carefully titrate CAR T cell doses, screen tumors for GSDME expression to anticipate CRS risk, consider co-administering agents that modulate macrophage activation to limit excessive inflammation, and monitor pyroptotic and inflammatory biomarkers in real time to guide adaptive treatment [135].